BRIEF published on 04/10/2025 at 19:05, 10 months 10 days ago TME Pharma strengthens its liquidity contract with Invest Securities Liquidity Contract Oncology INVEST SECURITIES Financial Markets TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 10 months 10 days ago Informations privilégiées / Autres communiqués TME Pharma augmente les ressources allouées au contrat de liquidité confié à Invest Securities pour renforcer la trésorerie. Détails des ressources disponibles après l'augmentation Contrat De Liquidité INVEST SECURITIES Trésorerie Ressources TME Pharma
PRESS RELEASE published on 04/10/2025 at 19:00, 10 months 10 days ago Inside Information / Other news releases TME Pharma increases resources for liquidity contract with Invest Securities by €5,000 to support cash balance and securities. Details of shares and cash balance provided Liquidity Contract INVEST SECURITIES Clinical-stage Biotechnology Resources TME Pharma
BRIEF published on 02/17/2025 at 08:05, 1 year ago TME Pharma présente sa feuille de route stratégique et ses initiatives pour 2025 Biotechnologie Partenariats Stratégiques Thérapie Contre Le Cancer Découverte De Médicaments NOX-A12
BRIEF published on 02/17/2025 at 08:05, 1 year ago TME Pharma Outlines 2025 Strategic Roadmap and Initiatives Strategic Partnerships Biotechnology Drug Discovery Cancer Therapy NOX-A12
PRESS RELEASE published on 02/17/2025 at 08:00, 1 year ago Inside Information / Other news releases TME Pharma CEO Aram Mangasarian outlines key initiatives and milestones for 2025, including strategic partnerships, NOX-A12 clinical development, AI-driven drug discovery, and financial updates Strategic Partnerships Clinical Development CEO Message TME Pharma 2025 Initiatives
BRIEF published on 01/29/2025 at 08:05, 1 year ago TME Pharma and aimed analytics: Innovative partnership for drug discovery through AI Biotechnology Artificial Intelligence Partnership Cancer Drugs
BRIEF published on 01/29/2025 at 08:05, 1 year ago TME Pharma et aimed analytics : Partenariat innovant pour la découverte de médicaments par l'IA Biotechnologie Partenariat Intelligence Artificielle Cancer Médicaments
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year ago Inside Information / Other news releases TME Pharma collaborates with aimed analytics for AI-driven drug discovery, strengthening capabilities for strategic transactions. The partnership utilizes AI to accelerate drug development and optimize existing therapies Strategic Partnerships Cancer Treatment TME Pharma AI-driven Drug Discovery Aimed Analytics
PRESS RELEASE published on 01/29/2025 at 08:00, 1 year ago Informations privilégiées / Autres communiqués TME Pharma annonce une collaboration avec aimed analytics pour optimiser la découverte de médicaments par IA, renforçant son profil stratégique Collaboration IA Médicaments TME Pharma Aimed Analytics
Published on 02/20/2026 at 20:15, 1 hour 34 minutes ago Lithium South Announces Results of its Annual and Special Meeting of Securityholders
Published on 02/20/2026 at 20:15, 1 hour 34 minutes ago Verdera Energy Announces Closing of Qualifying Transaction
Published on 02/20/2026 at 18:30, 3 hours 19 minutes ago Sparta Updates Delay in Filing Annual Financial Statements
Published on 02/20/2026 at 15:45, 6 hours 4 minutes ago Revolve Announces Closing of Initial US$10 Million Advance on Strategic Financing With Callaway
Published on 02/20/2026 at 14:30, 7 hours 19 minutes ago Norse Gold Announces Application for Reactivation to TSX-V, Private Placement Financing and Stock Options Grant
Published on 02/20/2026 at 18:36, 3 hours 13 minutes ago EQS-Adhoc: innoscripta SE: Management Board Proposes Dividend of EUR 4.00 per Share
Published on 02/20/2026 at 18:31, 3 hours 18 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/20/2026 at 18:00, 3 hours 49 minutes ago Leclanché conclut un accord de financement d’un montant de CHF 16,7 millions pour soutenir ses opérations à court terme
Published on 02/20/2026 at 18:00, 3 hours 49 minutes ago Leclanché Secures Financing Arrangement in the amount of CHF 16.7 million to Support Near-Term Operations
Published on 02/20/2026 at 19:29, 2 hours 20 minutes ago SFPI GROUP: Liquidity agreement report S2 2025
Published on 02/20/2026 at 19:29, 2 hours 20 minutes ago SFPI GROUP: bilan du contrat de liquidité S2 S025
Published on 02/20/2026 at 18:00, 3 hours 49 minutes ago TERACT - Résiliation du contrat de liquidité
